Immunotherapy includes strategies to enhance immune cell activation in patients towards the cancer, as well as cell-based therapies were patients receive genetically modified immune cells targeting cancer cells. Currently existing therapies on the market are associated with often severe side-effects and are limited to select patient groups. To broaden the applicability of immunotherapy and reduce side-effects, Cellmover currently focuses on two strategies:
1. Developing products aimed at increasing homing of therapeutic immune cells to tumors, and
2. Optimizing Cellmover's unique Immuno:Shield, a therapeutic agent desigend to increase survival and persistence of immune cells within the tumor microenvironment.
Contrary to products on the market, Immuno:Shield will have a broader applicability and primarily function within the tumor microenvironment reducing side-effects currently associated with immunotherapies.